Top 10 Deals of 2023: Kindbody Announces $100 Million Raise

This week we reflect on the remarkable trajectory of Kindbody’s growth, applauding their substantial fundraising achievements, underscoring the positivity it brings to the women’s health sector.

Kindbody, a prominent tech-driven fertility and family building benefits provider, has secured $100 Million in funding from Perceptive Advisors, a renowned life sciences investment firm. This takes Kindbody’s total funding to over $290 Million, and its valuation to $1.8 Billion. This milestone cements its status as the largest women-owned fertility company that caters to both employers and the general public. Kindbody’s future plans include opening new clinics in underserved regions of the United States and improving its care model, aiming to achieve top-tier clinical outcomes.

Infertility rates are on the rise, according to the World Health Organization, 1 in 6 couples will experience infertility in their lifetime. By 2026, the global market for fertility treatments is estimated to be $27 billion. While advancements in reproductive medicine, particularly in IVF, offer hope to those struggling to conceive, this solution comes at a steep cost. The associated costs can amount to tens of thousands of dollars for a single cycle, with limited insurance coverage, leaving a significant population without the means to pursue parenthood.

Determining the exact reasoning behind the increasing prevalence of infertility is complex and can be attributed to several factors, including delayed childbearing, lifestyle choice and environmental implications. With a clear need for affordable fertility solutions, early-stage companies are stepping up to the plate, tackling the infertility market from new, innovative angles.

Here are venture backed companies leading the charge on IVF affordability and accessibility:

Insurance / Employer Benefits

Maven Clinic– Series E – Maven is a digital health platform that connects individuals with a network of healthcare providers and experts, primarily in the fields of women’s health and family planning. It offers a range of services and resources related to women’s health, reproductive health, and family wellness.

Progyny– IPO – Progyny provides equitable and comprehensive fertility and family building benefits that lead to more healthy babies and pregnancies.

Carrot – Series C – Carrot helps people through fertility preservation, male-factor infertility, IVF, pregnancy and postpartum, adoption, gestational surrogacy, menopause, and more by leveraging their vetted network of clinics and agencies.

Invi– Pre-Seed – Invi is a women’s health and family-forward insurance product to cover the costs of IVF for employees and their partners.

Fertility Financing

Future Family – Series B – Future Family is a healthcare company that focuses on fertility and family planning services, and IVF financing while offering a range of services and solutions related to fertility and reproductive health.

Sunfish– Seed – Whether you’re exploring IVF, surrogacy, egg freezing, or another path to parenthood, Sunfish can offer guidance and help you explore low-interest loans.

Gaia Fertility – Series A – Start each round of IVF by paying Gaia an insurance premium, making it a smaller upfront amount than your full treatment costs. When you have a child, pay back monthly for your treatments for up to 8 years.

Brick and Mortar Fertility Clinics

Spring Fertility– Series A – Spring Fertility is a fertility clinic franchise. It offers a variety of services, including in vitro fertilization (IVF), egg freezing, and donor sperm and eggs.

Mate Fertility– Series A – Mate partners with experienced ObGyn surgeons to provide expert and affordable fertility care with the oversight of board certified reproductive endocrinologist (REI) and PhD lab directors.


The IVF market will continue to grow and there has never been a better time to invest in these early stage companies.

Continue Reading

ASV Insights – Top 10 Deals of 2023: $425M Acquisition of Menopause CPG Company

This week we explore the acquisition of Bonafide Health, a significant deal in the Menopause space. This strategic move marks a pivotal shift, bringing much-needed attention to an often overlooked area of women’s health.

Amboy Street Ventures Joins Granata Bio’s $14M Series A

Amboy Street Ventures (ASV) is excited to announce its latest investment in Granata Bio.

Top 10 Deals of 2023: Imaware Acquires Binx Health’s STI Testing Business

This week we assess the acquisition of Binx Health, an at-home STI testing company and consider similar pioneers in the sexual health space.

ASV Insights – Top 10 Deals of 2023: $425M Acquisition of Menopause CPG Company

This week we explore the acquisition of Bonafide Health, a significant deal in the Menopause space. This strategic move marks a pivotal shift, bringing much-needed attention to an often overlooked area of women’s health.

Amboy Street Ventures Joins Granata Bio’s $14M Series A

Amboy Street Ventures (ASV) is excited to announce its latest investment in Granata Bio.

Fast track our industry.
Get in touch today.